In BC, EMT activation is prominent in HER2-positive breast cancer stem cells, which exhibit radioresistance, drug resistance, and poor clinical outcomes, while EMT inhibition may mitigate treatment resistance and metastasis by suppressing HER2 expression (18). Here, ERBB2 is linked to breast carcinoma.